Fri, February 26, 2021

Difei Yang Maintained (SRPT) at Strong Buy with Increased Target to $160 on, Feb 26th, 2021

Difei Yang of Mizuho, Maintained "Sarepta Therapeutics, Inc." (SRPT) at Strong Buy with Increased Target from $158 to $160 on, Feb 26th, 2021.

Difei has made no other calls on SRPT in the last 4 months.



There are 8 other peers that have a rating on SRPT. Out of the 8 peers that are also analyzing SRPT, 5 agree with Difei's Rating of Hold. Following are those relevant analyst calls for the last 4 months


  • Joel Beatty of "Citigroup" Downgraded from Strong Buy to Hold and Held Target at $108 on, Tuesday, January 12th, 2021
  • Colin Bristow of "UBS" Downgraded from Strong Buy to Hold on, Monday, January 11th, 2021
  • Danielle Brill of "Raymond James" Downgraded from Buy to Hold on, Friday, January 8th, 2021
  • Martin Auster of "Credit Suisse" Maintained at Hold with Decreased Target to $73 on, Friday, January 8th, 2021
  • Matthew Harrison of "Morgan Stanley" Downgraded from Buy to Hold and Decreased Target to $95 on, Friday, January 8th, 2021


These are the ratings of the 3 analyists that currently disagree with Difei


  • Anupam Rama of "JP Morgan" Downgraded from Buy to Sell and Held Target at $96 on, Friday, January 8th, 2021
  • Chad Messer of "Needham" Maintained at Strong Buy with Decreased Target to $166 on, Friday, January 8th, 2021
  • Joseph Schwartz of "SVB Leerink" Maintained at Buy with Decreased Target to $125 on, Friday, January 8th, 2021